Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short vs Standard Duration Boceprevir in Asian HCV Genotype 1
NCT01945294Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2013
- Primary completion
- Aug 2015
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, open-label trial of boceprevir in hepatitis C (HCV) (3 arms), sponsored by Merck & Co. Primary endpoint: Sustained Viral Response at Follow-up Week 12. Started Oct 2013; status: completed.
02
Drugs
boceprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01945294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01945294.